SLC2A3 and non-small cell lung carcinoma: Atorvastatin (in combination with tyrosine kinase inhibitors, TKI) showed a specific in vitro/in vivo action against TKI resistant NSCLC cells. Inhibition of Cav1 and GLUT 3 [83]